Insulin-Dependent Diabetes Mellitus 12
16 drugs in active Insulin-Dependent Diabetes Mellitus 12 trials · Updated 18 Nov 2026
Furthest along
2 in Phase 3
8 in Phase 2
Drugs
16
In active trials, any stage
Trials
15 active
No sub-diseases
Drugs16
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 3 | Jan 2027Phase 3 trial completes | |||
| Next date | Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Melanoma (Skin), Melanoma Stage III and 5 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | — | |||
| How it works | An antibody | ||||
| Also tested for | Melanoma, Melanoma (Skin) and 5 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 2 | Sep 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Metastatic Colorectal Cancer | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 2 | Sep 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Metastatic Colorectal Cancer | ||||
| Open drug page | |||||
— |
CSPC · Public 1093.HK |
Phase 1/2 | 3 Feb 2029Phase 1/2 trial completes | ||
| Next date | 3 Feb 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced/Metastatic Solid Tumors | ||||
| Open drug page | |||||
GB268not checked |
— |
Phase 1/2 | 1 Aug 2029Phase 1/2 trial completes | ||
| Next date | 1 Aug 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Breast Cancer (Locally Advanced or Metastatic) | ||||
| Open drug page | |||||
Artificial immunoglobulin |
Phase 2 | 30 Sep 2029Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 30 Sep 2029 · Phase 2 trial completes | ||||
| Also tested for | Colon Cancer | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Advanced Solid Tumor, Metastatic Solid Tumor and 7 more | ||||
| Open drug page | |||||
PD-1 antibody |
Merck & Co. · Public MRK |
Phase 1/2 | — | ||
| Also tested for | Advanced Solid Tumor, Metastatic Solid Tumor and 7 more | ||||
| Open drug page | |||||
CTLA-4 antibody |
AstraZeneca · Public AZN |
Phase 2 | — | ||
| How it works | A cancer drug that hits three targets | ||||
| Also tested for | Unresectable Pleural or Peritoneal Malignant Mesothelioma | ||||
| Open drug page | |||||
No drugs match “”.
How trials write it5
The conditions trials list that we place on Insulin-Dependent Diabetes Mellitus 12 itself, with their active trials
Solid Tumor Cancer 16Advanced Clear Cell Renal Cell Carcinoma 3Healthy Male Volunteers 1Advanced Or Metastatic Solid Tumor Malignancies 1Metastatic Sarcoma 1
About
- Summary
- 16 drugs are in active Insulin-Dependent Diabetes Mellitus 12 trials: 2 in Phase 3, 14 earlier. The next Phase 3 result expected is BCD-217’s, Jan 2027. Updated 18 Nov 2026.
- Registry term
- Diabetes Mellitus, Insulin-Dependent, 12
- Counts
- Active trials the registry tags with the term or a term under it, at any stage. A search also reads trial titles and drug names, so its counts differ.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026